Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Clonal Hematopoiesis Can Precede AML with Defining Cytogenetic Abnormalities - the Frequencies Vary Considerably

Anetta Marcinek, Constance Regina Baer, Stephan Hutter, Manja Meggendorfer, Torsten Haferlach, Wolfgang Kern, Claudia Haferlach

Blood (2024) 144 (Supplement 1): 4318.

https://doi.org/10.1182/blood-2024-204966

Published: 2024

Journal Articles

Accomplices in Cure: Blinatumomab + Dasatinib Reduces TCR Signaling and Effector Function Stronger Than Ponatinib and Ameliorates T-Cell Exhaustion

Nora Philipp, Anetta Marcinek, Gerulf Hänel, Daniel Nixdorf, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 1511.

https://doi.org/10.1182/blood-2023-179286

Published: 2023

Journal Articles

Single-Cell Transcriptomic Profiling of T Cells from Blinatumomab-Treated Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Reveals Circulating CD8 T Cell Subsets Associated with Treatment Response

Francesco Corrado, Jan Wulf, Tobias Straub, Daniel Nixdorf, Anetta Marcinek, Nora Philipp, Chang-Feng Chu, Christina Zielinski, Michael von Bergwelt-Baildon, Viktoria Blumenberg, Maryam Kazerani, Marion Subklewe, Veit L. Buecklein

Blood (2023) 142 (Supplement 1): 600.

https://doi.org/10.1182/blood-2023-188970

Published: 2023

Journal Articles

The Battle within: AML´s p53 Strategies to Evade T-Cell Attack

Lis Winter, Lea Pawlowsky, Anetta Marcinek, Bettina Brauchle, Amelie Muth, Maryam Kazerani, Agnese Petrera, Roman Kischel, Alica Joana Emhardt, Maja Rothenberg-Thurley, Annika Maria Dufour, Karsten Spiekermann, Michael Andreeff, Naval Daver, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 1411.

https://doi.org/10.1182/blood-2023-173826

Published: 2023

Journal Articles

Two Players, One Goal: BiTE ® Vs CART Targeting FLT3 in AML

Lisa Rohrbacher, Daniel Nixdorf, Helena Stadler, Bettina Brauchle, Florian Märkl, Nora Philipp, Gerulf Hänel, Anetta Marcinek, Maryam Kazerani, Alica Joana Emhardt, Giulia Magno, Rebecca L. Goldstein, Tobias Straub, Sebastian Kobold, Tara L. Chapman-Arvedson, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 3444.

https://doi.org/10.1182/blood-2023-177922

Published: 2023

Journal Articles

Beyond Mitigating Immune-Related Adverse Events: Glucocorticoids Ameliorate Bispecific Antibody-Mediated T-Cell Exhaustion I n Vitro

Amelie Muth, Nora Philipp, Anetta Marcinek, Tobias Straub, Lis Winter, Gerulf Hänel, Daniel Nixdorf, Lisa Rohrbacher, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 5389.

https://doi.org/10.1182/blood-2023-174258

Published: 2023

Journal Articles

WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice

Maryam Ghalandary, Yuqiao Gao, Diana Amend, Ginte Kutkaite, Binje Vick, Karsten Spiekermann, Maja Rothenberg-Thurley, Klaus H. Metzeler, Anetta Marcinek, Marion Subklewe, Michael P. Menden, Vindi Jurinovic, Ehsan Bahrami, Irmela Jeremias

Blood (2023) 141 (8): 955–960.

https://doi.org/10.1182/blood.2022016411

Published: 2023

Includes: Supplemental data

Journal Articles

The Race Is on: BiTE Vs CART As FLT3-Directed Immunotherapies in AML

Lisa Rohrbacher, Daniel Nixdorf, Helena Stadler, Bettina Brauchle, Florian Märkl, Nora Phillip, Gerulf Hänel, Anetta Marcinek, Maryam Kazerani, Rebecca Goldstein, Michael von Bergwelt, Sebastian Kobold, Veit L Buecklein, Tara Chapman-Arvedson, Marion Subklewe

Blood (2022) 140 (Supplement 1): 10233–10234.

https://doi.org/10.1182/blood-2022-158452

Published: 2022

Journal Articles

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

Blood (2022) 140 (10): 1104–1118.

https://doi.org/10.1182/blood.2022015956

Published: 2022

Includes: Supplemental data

Journal Articles

Evolving Exhaustion of T Cells during the Course of the Disease in AML Can be Abrogated By CD33 BiTE ® Construct Mediated Cytotoxicity

Maryam Kazerani Pasikhani, Anetta Marcinek, Bettina Brauchle, Jonathan Jonas Taylor, Helena Domínguez Moreno, Maria Solovey, Frank Ziemann, Nora Zieger, Andrea Terrasi, Benjamin Tast, Karsten Spiekermann, Klaus H. Metzeler, Tobias Straub, Gunnar Schotta, Roman Kischel, Veit L Buecklein, Marion Subklewe

Blood (2021) 138 (Supplement 1): 1172.

https://doi.org/10.1182/blood-2021-150351

Published: 2021

Journal Articles

Treatment-Free Intervals during CD19xCD3 BiTE ® Construct-Mediated T-Cell Stimulation Induce Functional Reinvigoration and Transcriptional Reprogramming of Exhausted T Cells

Blood (2021) 138 (Supplement 1): 513.

https://doi.org/10.1182/blood-2021-150178

Published: 2021

Journal Articles

CD33 BiTE ® Construct Mediated Immunological Synapse Formation and Downstream Signaling in T Cells Is Dependent on Expression of Costimulatory Molecules on Target Cells

Anetta Marcinek, Bettina Brauchle, Gerulf Hänel, Sonja M Lacher, Nora Zieger, Roman Kischel, Michael von Bergwelt, Karsten Spiekermann, Sebastian Theurich, John R James, Veit L Buecklein, Marion Subklewe

Blood (2021) 138 (Supplement 1): 2237.

https://doi.org/10.1182/blood-2021-146488

Published: 2021

Journal Articles

Augmenting Efficacy of T-Cell Bispecific Antibodies in AML through a Tumor Stroma-Targeted 4-1BB Agonist

Gerulf Hänel, Anne-Sophie Neumann, Vesna Pulko, Christina Claus, Alexandra Leutbecher, Anetta Marcinek, Nora Zieger, Veit L Buecklein, Pablo Umana, Christian Klein, Marion Subklewe

Blood (2021) 138 (Supplement 1): 1178.

https://doi.org/10.1182/blood-2021-146762

Published: 2021

Journal Articles

Treatment-Free Intervals Mitigate T-Cell Exhaustion Induced By Continuous CD19xCD3-BiTE® Construct Stimulation in Vitro

Nora Zieger, Alyssa Nicholls, Jan Wulf, Gerulf Hänel, Maryam Kazerani Pasikhani, Veit Buecklein, MD, Bettina Brauchle, Anetta Marcinek, Daniel Nixdorf, Lisa Rohrbacher, Michaela Scheurer, Roman Kischel, MD, Karsten Spiekermann, MD, Oliver Weigert, MD, Sebastian Theurich, MD, Michael von Bergwelt, MD PhD, Marion Subklewe, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-137421

Published: 2020

Journal Articles

Exploiting an Anti-CD3/CD33 Bispecific Antibody to Redirect Donor T Cells Against HLA Loss Leukemia Relapses

Pier Edoardo Rovatti, MD, Laura Zito, MSc, Eleonora Draghi, MSc, Monika Herrmann, PhD, Anetta Marcinek, MSc, Bettina Brauchle, MSc, Cesare Covino, MSc, Mattia Di Bono, MSc, Matteo Giovanni Carrabba, MD, Massimo Bernardi, MD, Karl-Peter Hopfner, PhD, Cristina Toffalori, PhD, Fabio Ciceri, MD, Marion Subklewe, MD, Luca Vago, MD PhD

Blood (2019) 134 (Supplement_1): 513.

https://doi.org/10.1182/blood-2019-126641

Published: 2019

Journal Articles

Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia

Monika Herrmann, Christina Krupka, Katrin Deiser, Bettina Brauchle, Anetta Marcinek, Ana Ogrinc Wagner, Felicitas Rataj, Ralph Mocikat, Klaus H. Metzeler, Karsten Spiekermann, Sebastian Kobold, Nadja C. Fenn, Karl-Peter Hopfner, Marion Subklewe

Blood (2018) 132 (23): 2484–2494.

https://doi.org/10.1182/blood-2018-05-849802

Published: 2018

Includes: Supplemental data

Journal Articles

The Ratio of Costimulatory Vs Coinhibitory Molecules on AML Cells Determines the CD33-BiTE ® Mediated T-Cell Response

Anetta Marcinek, MSc, Bettina Brauchle, MSc, Dragica Udiljak, Roman Kischel, MD, Peter Kufer, MD, Karsten Spiekermann, MD, Michael von Bergwelt, MD, Felix S. Lichtenegger, MD, Marion Subklewe, MD

Blood (2018) 132 (Supplement 1): 1349.

https://doi.org/10.1182/blood-2018-99-116297

Published: 2018

NARROW

Clonal Hematopoiesis Can Precede AML with Defining Cytogenetic Abnormalities - the Frequencies Vary Considerably

Accomplices in Cure: Blinatumomab + Dasatinib Reduces TCR Signaling and Effector Function Stronger Than Ponatinib and Ameliorates T-Cell Exhaustion

Single-Cell Transcriptomic Profiling of T Cells from Blinatumomab-Treated Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Reveals Circulating CD8 T Cell Subsets Associated with Treatment Response

The Battle within: AML´s p53 Strategies to Evade T-Cell Attack

Two Players, One Goal: BiTE ® Vs CART Targeting FLT3 in AML

Beyond Mitigating Immune-Related Adverse Events: Glucocorticoids Ameliorate Bispecific Antibody-Mediated T-Cell Exhaustion I n Vitro

WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice

The Race Is on: BiTE Vs CART As FLT3-Directed Immunotherapies in AML

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

Evolving Exhaustion of T Cells during the Course of the Disease in AML Can be Abrogated By CD33 BiTE ® Construct Mediated Cytotoxicity

Treatment-Free Intervals during CD19xCD3 BiTE ® Construct-Mediated T-Cell Stimulation Induce Functional Reinvigoration and Transcriptional Reprogramming of Exhausted T Cells

CD33 BiTE ® Construct Mediated Immunological Synapse Formation and Downstream Signaling in T Cells Is Dependent on Expression of Costimulatory Molecules on Target Cells

Augmenting Efficacy of T-Cell Bispecific Antibodies in AML through a Tumor Stroma-Targeted 4-1BB Agonist

Treatment-Free Intervals Mitigate T-Cell Exhaustion Induced By Continuous CD19xCD3-BiTE® Construct Stimulation in Vitro

Exploiting an Anti-CD3/CD33 Bispecific Antibody to Redirect Donor T Cells Against HLA Loss Leukemia Relapses

Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia

The Ratio of Costimulatory Vs Coinhibitory Molecules on AML Cells Determines the CD33-BiTE ® Mediated T-Cell Response

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only